PTC Therapeutics, Inc.
S&P 600
$66.06
-1.94%
Delayed · cached 15 min
Fair value analysis
PTCT
PTC Therapeutics, Inc.
$66.06
Close used for this calculation
$137.94Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
58/100
Quality radar
Consensus fair value
$137.94
Below FV▲ +108.8% against the close used
Model range $103.23 – $155.60
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$103.23Fair value$137.94Bull$155.60
FairClose
52-week traded range
52W low $57.8452W high $89.55
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
PTC Therapeutics, Inc. closed at $66.06, 52.1% below the consensus fair value of $137.94 drawn from 5 valuation models.
Financial DNA score 58/100 — Good. P/E of 8.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$150.02
+127.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
P/E Fair Value
$155.60
+135.5%
EPS × 20x (sector P/E)
EPS=7.78, Sector P/E=20x
EV/EBITDA
$103.23
+56.3%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=905.75M
Reverse DCF
$66.06
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -4.6% | Historical: 0%
Margin of Safety
$114.61
+73.5%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=152.81, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.